Advaxis — Corporate Update (March 2013)
27 slides from Advaxis's corporate update, Mar 7, 2013
Slide 1: 2013 Business Outlook Conference Call and Webcast
2013 Business Outlook Conference Call and Webcast Thomas A. Moore, CEO Advaxis, Inc. (OTC BB: ADXS) Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward - looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies and other business developments, statements as to the development of new constructs, expectations as to the adequacy of our c
Slide 3: Thomas A. Moore, Chairman and CEO
Thomas A. Moore Chairman and CEO 3 3
Slide 4: Thomas A. Moore, Chairman / CEO and management team
Thomas A. Moore, Chairman / CEO 25 years experience in healthcare, executive management and business development. As CEO of Nelson Communications, engineering the sale of the company to Publicis Group for $246 million. President of Procter & Gamble ’ s (NYSE: PG) worldwide healthcare products busine
Slide 5: Advaxis Overview
Advaxis Overview • Advaxis is headquartered in Princeton, NJ • Dr. Yvonne Paterson developed technology at the University of Pennsylvania in the early 1990s and licensed exclusively to Advaxis in 2002 • Advaxis proprietary platform: 2 key elements: – Live attenuated Listeria monocytogenes ( Lm ): •
Slide 6: Ongoing Studies
5 Ongoing Studies with ADXS - HPV – Phase 1 refractory cervical cancer (15 patients)* – Phase 2 refractory cervical cancer (110 patients)** – Phase 2 refractory cervical cancer (67 patients) – Phase 2 cervical neoplastic dysplasia (CIN) 2/3 (120 patients)** – Phase 1/2 head and neck cancer (27 patie
Slide 7: Advaxis Clinical Pipeline
Advaxis Clinical Pipeline Clinical Pipeline Construct Indication Pre Phase 1 Phase 2 ADXS - HPV Cervical Cancer, India ADXS - HPV Cervical Cancer, US, GOG ADXS - HPV CIN 2/3, US ADXS - HPV Head & Neck Cancer, CRUK ADXS - HPV Anal Cancer, BrUOG ADXS - PSA Prostate Cancer ADXS - cHER2 Canine Osteosarc
Slide 8: Proprietary Platform Can Create Multiple Product Candidates
Proprietary Platform Can Create Multiple Product Candidates Lm - LLO Immunotherapy Tumor Antigen Tumor model Reference ADXS11 - 001 HPV16 - E7 TC - 1 Gunn et al 2001 ADXS31 - 142 Prostate Specific antigen TRAMPC1 /PSA Shahabi et al. 2008, Wallecha et al. 2009 ADXS31 - 164 Her2/neu Chimera NT - 2 Bre
Slide 9: 2012 Vaccine Industry Excellence Award: Best Therapeutic Vaccine
ViE Vaccine Industry Excellence Vv" “AWARDS 2012 Winner Best Therapeutic Vaccine (approved or in development)
Slide 10: 2012 Achievements
2012 Achievements • Secured access to $10M committed equity line • Eliminated ~ 80% of debt • Achieved proof of concept for ADXS - HPV • Bolstered existing management team 10 10
Slide 11: Overarching 2013 Objectives
Overarching 2013 Objectives 1. Continue to advance lead ADXS - HPV toward registration development program 2. Continue to significantly strengthen financial position 11 11
Slide 12: Daniel J. O'Connor, Chief Business Development and Legal Officer
Daniel J. O ’ Connor Senior Vice President Chief Business Development and Legal Officer 12 12
Slide 13: PhRMA 2012 Report: Medicines in Development for Cancer
13 Phrma.org 2012 Report Medicines in Development for Cancer Source http://www.phrma.org/sites/default/files/1000/phrmamedicinesindevelopmentcancer2012.pdf 13
Slide 14: Cervical Cancer Products in Development
14 Cervical cancer Product Name Sponsor Indication Development Status ADXS - HPV Advaxis Princeton, NJ cervical cancer, cervical intraepithelial neoplasia Phase 2 PM - 00104 PharmaMar Madrid, Spain (see also sarcoma, other) Phase 2 PV701 (replication - competent oncolytic virus) Wellstat Biologics G
Slide 15: Growth in HPV Mediated Cancers Drives Wider Potential
Growth in HPV mediated cancers… drives even wider potential for ADXS - HPV ~527,000 Incidence per year Worldwide (12,000 US) 15
Slide 16: Growth in HPV Mediated Cancers Drives Wider Potential
Growth in HPV mediated cancers… drives even wider potential for ADXS - HPV ~80,000 Incidence per year ~86,000 Incidence per year ~27,000 Incidence per year ~13,000 Incidence per year ~99,000 Incidence per year ~527,000 Incidence per year Worldwide (12,000 US) 16
Slide 17: Robert Petit, Ph.D., VP Clinical Operations & Medical Affairs
Robert Petit, Ph.D. VP Clinical Operations & Medical Affairs 17 17
Slide 18: Disease Burden Is Concentrated in India, China and South America
Disease burden is concentrated: ~50% of cervical cancer burden exists in India, China & South America 18
Slide 19: Cervical Cancer is a Worldwide Problem
Cervical Cancer is a Worldwide Problem • According to WHO, ~ 630 million people are infected with one of the over 100 strains of HPV • Global prevalence of clinically pre - malignant HPV infections to be between 28 to 40 million women • Approximately 500,000 newly diagnosed cases of cervical cancer
Slide 20: Lead Indication: Phase 2 Cervical Cancer Study +/- Cisplatin
ADXS - HPV Lead Indication: Phase 2 Cervical Cancer Study +/ - Cisplatin Study Design Recurrent/ Refractory Cervical (N = 110) Arm A N = 55 ADXS Only Arm B N = 55 ADXS+Cisplatin Treatment Follow - up Phase Scans ADXS ADXS ADXS ADXS C C C C ADXS ADXS C ADXS 3m 6m 9m 12m R 3m 6m 9m 12m 18m 18m // // *
Slide 21: Preliminary Phase 2 Survival Data Compared to Historical Controls
6 mo. 9 mo. 12 mo. 18 mo. # Alive/N 71/109 39/88 23/70 6/36 % Survival 65% 44% 33% 17% Preliminary Phase 2 Data Show Encouraging Survival Compared to Historical Controls ADXS - HPV Preliminary Landmark Survival Data (as of October 22, 2012) *NCCN Guidelines: Plaxe SC, et. al., 2002, Cancer Chemother
Slide 22: Proof of Concept Achieved
Proof of Concept Achieved • ADXS - HPV is emerging as an active agent in recurrent/refractory cervical cancer with a predictable safety profile • Apparent prolonged survival, durable complete and partial tumor reductions, as well as stabilization of disease have been observed with ADXS - HPV treatme
Slide 23: 2013 Clinical and Regulatory Objectives
2013 Clinical and Regulatory Objectives • Analyze Phase 2 data and work to optimize dose and schedule • Proceed with clinical plan with the advice and collaboration of global thought leaders in cervical cancer • Finalize clinical plan and consult with regulatory authorities to advance ADXS - HPV to
Slide 24: Mark J. Rosenblum, Chief Financial Officer
Mark J. Rosenblum Senior Vice President Chief Financial Officer 24 24
Slide 25: Financial Overview
Financial Overview Exchange / Ticker OTC BB: ADXS Cash Raised Since Inception - approximately $40M Committed Equity Financing Facility $10M Monthly Cash Spend (including clinical) $600K Debt non - affiliate at Y/E 2012 Down from $9M Year Ago <$2.0M Common Stock Outstanding 515.1M Warrants 100M Optio
Slide 26: Clinical Milestones 2013
Early Q2 2013 Q2 2013 H2 2013 H1 2014 • Announce CIN 2/3 mid - dose Cohort 2 data • Announce 12 - month survival data from India study • Announce final Phase 2 cervical cancer results • Initiate the Phase 2 High - dose Cohort 3 CIN 2/3 • File IND with the FDA for ADXS - PSA 26 By end of 2013 • Compl
Slide 27: Thank You
Thank You Advaxis Inc. (OTC BB: ADXS) 305 College Road East Princeton, NJ 08540 609.452.9813 [email protected] www.advaxis.com